Pibrentasvir | CAS#1353900-92-1 | NS5A inhibitor

MedKoo Cat#: 528903 | Name: Pibrentasvir

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pibrentasvir is a potent NS5A inhibitor used in combination with glecaprevir for the treatment of chronic hepatitis C virus (HCV) infection. It exhibits broad-spectrum activity against all major HCV genotypes (GT1-6) with picomolar potency. In biochemical assays, pibrentasvir demonstrated EC50 values ranging from 3–366 pM across different genotypes, indicating strong antiviral efficacy. In cellular replicon assays, its EC50 values were 5–500 pM, with the highest potency observed against GT1a, GT1b, and GT2a. Pharmacokinetic studies show a high plasma protein binding (>99%) and a long half-life, allowing for once-daily dosing. Clinical trials confirmed its high barrier to resistance and effectiveness in achieving sustained virologic response (SVR12) rates exceeding 95% in treatment-naïve and experienced patients, including those with compensated cirrhosis.

Chemical Structure

Pibrentasvir

CAS#1353900-92-1 (free)

Theoretical Analysis

MedKoo Cat#: 528903

Name: Pibrentasvir

CAS#: 1353900-92-1 (free)

Chemical Formula: C57H65F5N10O8

Exact Mass: 1112.4907

Molecular Weight: 1113.20

Elemental Analysis: C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50

Price and Availability

Size	Price	Availability
25mg	USD 120.00	Ready to ship
50mg	USD 200.00	Ready to ship
100mg	USD 320.00	Ready to ship
200mg	USD 550.00	Ready to ship
500mg	USD 1,250.00	Ready to ship
1g	USD 2,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1821461-48-6 (butanamine hydrate) 1353900-92-1 (free)

Synonym

ABT-530; ABT530; ABT 530, A-1325912; A 1325912; A1325912; A-1325912.0; A 1325912.0; A1325912.0; Pibrentasvir.

IUPAC/Chemical Name

dimethyl ((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

InChi Key

VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi Code

InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

SMILES Code

FC1=CC=C(C=C1)C2CCN(CC2)C3=C(C=C(C=C3F)N4[C@H](CC[C@@H]4C5=C(F)C=C6NC([C@@H]7CCCN7C([C@@H](NC(OC)=O)[C@H](OC)C)=O)=NC6=C5)C8=C(C=C9C(N=C([C@@H]%10CCCN%10C([C@@H](NC(OC)=O)[C@H](OC)C)=O)N9)=C8)F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#E7O11S122

View CoA: current batch, Lot#E7O12S05

QC Data

View QC data: current batch, Lot#E7O11S122

View QC data: current batch, Lot#E7O12S05

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Pibrentasvir (ABT-530) is a hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM.

In vitro activity:

Pibrentasvir is a next-generation NS5A inhibitor with potent (EC50s, 1.4 to 5.0 pM) and pan-genotypic antiviral activity against HCV replicons containing NS5A from all major HCV genotypes. Pibrentasvir demonstrated similar in vitro antiviral activities against replicons with NS5A from a panel of clinical samples of genotypes 1 to 6, indicating that pibrentasvir can inhibit HCV with clinically relevant sequence diversity in NS5A. In addition, pibrentasvir retained its activity against common NS5A amino acid substitutions that confer resistance to other NS5A inhibitors. It also demonstrated a high genetic barrier to resistance, selecting a small number or no colonies with resistance-conferring amino acid substitutions in replicons containing NS5A from genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Pibrentasvir was active against key resistance-associated amino acid substitutions for NS3/4A PIs or NS5B polymerase inhibitors. The combination of pibrentasvir with HCV inhibitors of other classes produced synergistic antiviral activity in vitro. Reference: Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02558-16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404558/

In vivo activity:

A research program to discover solubilizing prodrugs of the HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen atom via an oxymethyl linkage to allow for rapid and complete release of the drug for absorption following phosphate removal by intestinal alkaline phosphatase. These prodrugs have good hydrolytic stability properties and improved solubility compared to PIB, both in aqueous buffer (pH 7) and FESSIF (pH 5). TML prodrug 9 provided superior in vivo performance, delivering high plasma concentrations of PIB in PK studies conducted in mice, dogs, and monkeys. The improved dissolution properties of these phosphate prodrugs provide them the potential to simplify drug dosage forms for PIB-containing HCV therapy. Reference: J Med Chem. 2020 Oct 8;63(19):11034-11044. https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00956

	Solvent	mg/mL	mM
Solubility
	DMSO	20.0	18.00
	Ethanol	10.0	9.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,113.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02558-16. doi: 10.1128/AAC.02558-16. PMID: 28193664; PMCID: PMC5404558. 2. Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem. 2020 Oct 8;63(19):11034-11044. doi: 10.1021/acs.jmedchem.0c00956. Epub 2020 Sep 17. PMID: 32881503.

In vitro protocol:

In vivo protocol:

1. Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem. 2020 Oct 8;63(19):11034-11044. doi: 10.1021/acs.jmedchem.0c00956. Epub 2020 Sep 17. PMID: 32881503.

1: Liu CH, Chang YP, Kao JH. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review. Expert Opin Pharmacother. 2024 Aug 26:1-16. doi: 10.1080/14656566.2024.2396024. Epub ahead of print. PMID: 39169665. 2: Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, Yu ML. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry. J Formos Med Assoc. 2024 Aug 20:S0929-6646(24)00381-4. doi: 10.1016/j.jfma.2024.08.013. Epub ahead of print. PMID: 39168745. 3: Noskov S, Parulya O, Lutskova L, Arefeva A, Protsenko E, Banko V, Radaeva K, Matvienko I, Gefen M, Karnakova P, Knyazeva A, Komarov T, Archakova O, Shohin I. Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers. Clin Pharmacol Drug Dev. 2024 Aug 14. doi: 10.1002/cpdd.1463. Epub ahead of print. PMID: 39140163. 4: Kleiboeker HL, Prom A, Patel S. Efficacy of dose-reduced glecaprevir- pibrentasvir in lung transplant recipients on maintenance cyclosporine from donors with hepatitis C viremia. Transpl Infect Dis. 2024 Aug 13:e14357. doi: 10.1111/tid.14357. Epub ahead of print. PMID: 39136183. 5: Fahnøe U, Madsen LW, Christensen PB, Sølund CS, Mollerup S, Pinholt M, Weis N, Øvrehus A, Bukh J. Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients. Microbiol Spectr. 2024 Jul 25:e0064124. doi: 10.1128/spectrum.00641-24. Epub ahead of print. PMID: 39051781. 6: Toyodome A, Mawatari S, Eguchi H, Takeda M, Kumagai K, Taniyama O, Ijuin S, Sakae H, Tabu K, Oda K, Ikeda M, Ido A. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. Sci Rep. 2024 Jul 16;14(1):16363. doi: 10.1038/s41598-024-67169-5. PMID: 39013947; PMCID: PMC11252252. 7: Gonzales-Zamora JA, Quispe-Vicuña C, Reategui-Garcia ME, Araoz-Salinas JM, Ccami-Bernal F, Morocho-Alburqueque N, Espinoza-Herreros JP, Layme J, Aquino- Sandoval G, Campos VYM, Alave J. Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review. J Clin Med. 2024 Jun 30;13(13):3867. doi: 10.3390/jcm13133867. PMID: 38999433; PMCID: PMC11242551. 8: Makovich Z, Radosavljevic I, Chapyala S, Handley G, Pena L, Mok S, Friedman M. Rationale for Hepatitis C Virus Treatment During Hematopoietic Stem Cell Transplant in the Era of Novel Direct-Acting Antivirals. Dig Dis Sci. 2024 Jul 11. doi: 10.1007/s10620-024-08541-3. Epub ahead of print. PMID: 38990268. 9: Wiese J, Derian NA, Ghimire S, Bambhroliya Z, Joshi T. Glecaprevir- Pibrentasvir and Ethinyl Estradiol-Induced Liver Injury in a Patient Without Cirrhosis. Cureus. 2024 Jun 8;16(6):e61980. doi: 10.7759/cureus.61980. PMID: 38983976; PMCID: PMC11232366. 10: Hartley C, Van T, Karnsakul W. Direct-Acting Antiviral Agents in Prevention of Maternal-Fetal Transmission of Hepatitis C Virus in Pregnancy. Pathogens. 2024 Jun 16;13(6):508. doi: 10.3390/pathogens13060508. PMID: 38921805; PMCID: PMC11206561. 11: Pol S, Thompson AJ, Collins M, Venier E, Cotte L, Laguno Centeno M, Mera J, Reiberger T, Burroughs M, Semizarov DG, Iacob AM, Welhaven A, Fredrick LM, Doyle JS. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study. Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923. Epub ahead of print. PMID: 38768260. 12: Mbisa JL, Lapp Z, Bibby DF, Phillips LT, Manso CF, Packer S, Simmons R, Harris K, Mohan J, Chinnappan L, Leitner T, Bradshaw D. Identification of two novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals. J Infect Dis. 2024 May 8:jiae253. doi: 10.1093/infdis/jiae253. Epub ahead of print. PMID: 38717937. 13: Gillis B, Villanueva D, Marsh W, Afridi F, Danforth J, Thornberg M, Chaudhary V, Sharma R. Outcomes of Kidneys Transplanted From Hepatitis C Viremic Donors to Naive Recipients From an Appalachian Rural Kidney Transplant Program. Exp Clin Transplant. 2024 Mar;22(3):185-188. doi: 10.6002/ect.2024.0034. PMID: 38695587. 14: Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodríguez-Seguel E, Mateos B, Rodríguez M, Rosales Zabal JM, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Badia Aranda E, Hernández-Guerra M, Maté CJ, González- Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, Buti M. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2. PMID: 38695095. 15: Morita A, Tamaki N, Kobashi H, Mori N, Tsuji K, Takaki S, Hasebe C, Akahane T, Ochi H, Mashiba T, Urawa N, Fujii H, Mitsuda A, Kondo M, Ogawa C, Uchida Y, Narita R, Marusawa H, Kubotsu Y, Matsushita T, Shigeno M, Yoshida H, Tanaka K, Okamoto E, Kasai T, Ishii T, Okada K, Kurosaki M, Izumi N. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study. JGH Open. 2024 Apr 25;8(4):e13068. doi: 10.1002/jgh3.13068. PMID: 38681824; PMCID: PMC11046085. 16: Yang CC, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Kuo HT, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Yu ML. Real- World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan. Infect Dis Ther. 2024 Jun;13(6):1199-1213. doi: 10.1007/s40121-024-00968-5. Epub 2024 Apr 28. PMID: 38679663; PMCID: PMC11128429. 17: Flamm SL, Mangia A. Adherence in Hepatitis C Virus Treatment: What We Know. Semin Liver Dis. 2024 May;44(2):258-271. doi: 10.1055/a-2313-0111. Epub 2024 Apr 24. PMID: 38657680. 18: Shiller DD, Yao BB, Chen MJ, Orejudos A, Mostafa NM, Marcinak JF, Burroughs M, Boyle C. Phase 1 study of safety and tolerability of an oral contraceptive containing low-dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women. J Viral Hepat. 2024 Jul;31(7):409-415. doi: 10.1111/jvh.13946. Epub 2024 Apr 23. PMID: 38654438. 19: Wang DS, Phu A, McKee K, Strasser SI, Sheils S, Weltman M, Sellar S, Davis JS, Young M, Braund A, Farrell GC, Blunn A, Harding D, Ralton L, Muller K, Davison SA, Shaw D, Wood M, Hajkowicz K, Skolen R, Davies J, Tate-Baker J, Doyle A, Tuma R, Hazeldine S, Lam W, Edmiston N, Zohrab K, Pratt W, Watson B, Zekry A, Stephens C, Clark PJ, Day M, Park G, Kim H, Wilson M, McGarity B, Menzies N, Russell D, Lam T, Boyd P, Kok J, George J, Douglas MW. Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia. Open Forum Infect Dis. 2024 Mar 18;11(4):ofae155. doi: 10.1093/ofid/ofae155. PMID: 38651137; PMCID: PMC11034952. 20: Sánchez Suárez MM, Martín Roldán A, Cantudo Cuenca MR. Glecaprevir/pibrentasvir en combinación con ribavirina como terapia de rescate en hepatitis C crónica [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C]. Rev Esp Quimioter. 2024 Jun;37(3):283-284. Spanish. doi: 10.37201/req/020.2024. Epub 2024 Apr 19. PMID: 38638059; PMCID: PMC11094641.

1. Ohya K, Imamura M, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Abe-Chayama H, Hayes CN, Aikata H, Ishida Y, Tateno C, Song H, Miyayama Y, Hijikata M, Chayama K. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. Biochem Biophys Res Commun. 2021 Apr 28;559:78-83. doi: 10.1016/j.bbrc.2021.04.062. Epub ahead of print. PMID: 33932902.